Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II ProLindac + paclitaxel as second-line therapy in platinum-pretreated advanced ovarian cancer
2010-020030-25Phase 2Completed
- Sponsor
- Access Pharmaceuticals
- Start
- Jul 2010
- Modality
- Small Molecules, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AP5346 and paclitaxel in epithelial ovarian cancer (EOC) and ovarian cancer, sponsored by Access Pharmaceuticals. Primary endpoint: Objective response rate by RECIST 1.1 or GCIG-Rustin criteria. Started Jul 2010; status: completed.
02
Drugs
AP5346paclitaxel
03
Conditions
epithelial ovarian cancer (EOC)ovarian cancer
Beyond the preview
Go deeper on 2010-020030-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020030-25.